Jun 14 |
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
|
Jun 14 |
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
|
Jun 6 |
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
|
Jun 3 |
Lixte Biotechnology appoints Jan Schellens as CMO
|
Jun 3 |
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
|
May 20 |
LIXTE Biotechnology Holdings Provides Update on Recent Activities
|
May 8 |
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
|
Mar 27 |
Gold Moves Higher; Velo3D Shares Plummet
|
Mar 27 |
Lixte stock soars on preclinical data for lead drug LB-100
|
Mar 27 |
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
|